Similarly, the ACC/AHA 2024 guidelines also strongly advocate for the use of GLP-1 RAs and SGLT2is in PAD patients with T2DM to reduce the risk of MACEs, assigning this recommendation Class I, Level of Evidence A [10]. The gene discussed is GLP1R; the disease is peripheral arterial disease.